The big Covid-19 trials still to report
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Hope versus experience in glioblastoma
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
Ovid crashes out in Angelman syndrome
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
The promise and the perils of antigen testing
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
Glaxo moves up a place in the RSV treatment race
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Interest in Tyk2 might soon tick up
Pfizer is still the only big pharma to have followed Bristol's lead in going all-in on the mechanism.
Aducanumab: this time it’s personal
The focus shifts to whether the FDA will overrule its own panel and approve the Alzheimer’s project.
